Literature DB >> 24061852

Skeletal alterations in women affected by obesity.

Silvia Migliaccio1, Emanuela A Greco, Rachele Fornari, Lorenzo M Donini, Luigi Di Luigi, Andrea Lenzi.   

Abstract

Obesity has always been considered a protective factor for the skeleton and for osteoporosis. However, new epidemiologic and clinical data have shown that high level of fat mass might be a risk factor for osteoporosis and fragility fractures. Further, increasing evidences seem to indicate that the different components of metabolic syndrome (i.e. hypertension, increased triglycerides, and reduced high-density lipoprotein cholesterol) are also potential risk factors for the development of low bone mineral density and osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061852     DOI: 10.1007/s40520-013-0090-1

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  4 in total

1.  The Cooccurrence of Obesity, Osteoporosis, and Sarcopenia in the Ovariectomized Rat: A Study for Modeling Osteosarcopenic Obesity in Rodents.

Authors:  Zahra Ezzat-Zadeh; Jeong-Su Kim; P Bryant Chase; Bahram H Arjmandi
Journal:  J Aging Res       Date:  2017-06-01

2.  Correlation of the Lipid Profile, BMI and Bone Mineral Density in Postmenopausal Women.

Authors:  Radojka Bijelic; Jagoda Balaban; Snjezana Milicevic
Journal:  Mater Sociomed       Date:  2016-12

3.  MiR-141-3p promotes mitochondrial dysfunction in ovariectomy-induced sarcopenia via targeting Fkbp5 and Fibin.

Authors:  Hyunjung Lee; Young In Kim; Farida S Nirmala; Ji-Sun Kim; Hyo-Deok Seo; Tae Youl Ha; Young-Jin Jang; Chang Hwa Jung; Jiyun Ahn
Journal:  Aging (Albany NY)       Date:  2021-02-03       Impact factor: 5.682

4.  The Effects of 12-Weeks Whey Protein Supplements on Markers of Bone Turnover in Adults With Abdominal Obesity - A Post Hoc Analysis.

Authors:  Rasmus Fuglsang-Nielsen; Elin Rakvaag; Peter Vestergaard; Kjeld Hermansen; Søren Gregersen; Jakob Starup-Linde
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.